Director of Medicare and Deputy Administrator of CMS Chris Klomp speaks after U.S. President Donald Trump announced a deal with Pfizer to sell drugs at lower prices, in the Oval office of the White House in Washington on Sept. 30, 2025. Ken Cedeno/Reuters
The U.S. government has begun talks with pharmaceutical companies to turn President Donald Trump’s Most Favored Nation drug pricing policy into permanent law, Chris Klomp, chief counselor at the Department of Health and Human Services, told reporters on March 19.
“We’re also beginning to read in pharmaceutical companies to help them understand the nature of the legislative text, to see if they can buy in, if there’s a version we might reach,” Klomp said.
We had a problem loading this article. Please enable javascript or use a different browser. If the issue persists, please visit our help center.